Composition for the treatment of disease

Patent metadata

Field	Value
Publication number	US-9682101-B2
Application number	US-201414779412-A
Country	US
Kind code	B2
Filing date	Mar 25, 2014
Priority date	Mar 25, 2013
Publication date	Jun 20, 2017
Grant date	Jun 20, 2017

Abstract

A composition for use in the treatment of a condition or disorder related to mucosal barrier dysfunction in the gut, the composition comprising activated carbon. The condition may be, for example, pouchitis or proctitis.

First claim

The invention claimed is:

1. A method for treating a condition selected from the group consisting of proctitis, radiation proctitis, and pouchitis in a subject in need thereof, comprising administering to the subject an effective amount of a composition comprising activated carbon, wherein the method comprises orally administering an effective amount of a composition comprising:
(a) a core consisting of activated carbon;
(b) a first layer that provides an insoluble semipermeable membrane around the core, the first layer comprising a semipermeable material which is insoluble in water; and
(c) a second layer around the first layer which breaks down rapidly at pH 5 to 7 and/or which dissolves at a predetermined location in the gastrointestinal tract.

2. A method according to claim 1 , wherein the activated carbon has a particle size of from 0.001 to 1 mm.

3. A method according to claim 1 , wherein the activated carbon has a particle size of from 0.02 to 1 mm.

4. A method according to claim 1 , wherein the activated carbon has a particle size of from 0.05 mm to 1 mm.

5. A method according to claim 1 , wherein the activated carbon has a particle size of from 0.02 to 5.0 mm.

6. A method according to claim 1 , wherein the activated carbon has a particle size of from 0.6 to 1.2 mm.

7. A method according to claim 1 , wherein the activated carbon has an average particle size of from 0.2 mm to 0.3 mm.

8. A method according to claim 1 , wherein the activated carbon has an average particle size of from 0.15 mm to 1 mm.

9. A method according to claim 1 , wherein the activated carbon has an average particle size of from 0.15 mm to 0.3 mm.

10. A method according to claim 1 , wherein the composition comprises from 450 μg to 10 g activated carbon.

11. A method according to claim 1 , comprising orally administering said composition comprising said core, said first layer around said core, and said second layer around said first layer, wherein said second layer dissolves at pH 5 to 7.

12. A method according to claim 11 , wherein the insoluble semipermeable material of said first layer comprises one or more components selected from the group consisting of ethyl cellulose, glyceryl monostearate, cellulose acetate butyrate, dipolylactic acid, polyvinyl chloride, and a poly(meth)acrylate polymer.

13. A method according to claim 11 , wherein said first layer further comprises a water soluble material.

14. A method according to claim 13 , wherein said first layer further comprises a water soluble material comprising hydroxypropylmethyl cellulose (HPMC).

15. A method according to claim 13 , wherein the water soluble material is mixed with the insoluble semipermeable material in said first layer.

16. A method according to claim 13 , wherein the water soluble material is present in an amount of 0.1 to 30% by weight of the amount of the insoluble semipermeable material present in said first layer.

17. A method according to claim 13 , wherein the water soluble material is present in an amount of 2 to 25% by weight of the amount of the insoluble semipermeable material present in said first layer.

18. A method according to claim 1 , comprising orally administering said composition comprising said core, said first layer around said core, and said second layer around said first layer, wherein said second layer is an enteric layer comprising a material which remains substantially intact at pH 1 to 4.9, but which breaks down rapidly at pH 5 to 7.

19. A method according to claim 1 , comprising orally administering said composition comprising said core, said first layer around said core, and said second layer around said first layer, wherein second layer comprises one or more components selected from the group consisting of hypromellose-acetate-succinate; cellulose acetate trimellitate (CAT); cellulose acetate phthalate (CAP); anionic copolymers based on methylacrylate, methylmethacrylate and methacrylic acid; hydroxypropyl methylcellulose phthalate (HPMCP); hydroxypropylmethylcellulose acetate succinate (HPMCAS); methacrylic acid and ethyl acrylate copolymers; methacrylic acid and methyl methacrylate copolymers at a 1:1 ratio; methacrylic acid and methyl methacrylate copolymers at a 1:2 ratio; polyvinyl acetate phthalate (PVAP), and shellac resins.

20. A method according to claim 1 , wherein the activated carbon is the sole active pharmaceutical ingredient in said composition.

21. A method according to claim 1 , comprising orally administering said composition comprising said core, said first layer around said core, and said second layer around said first layer, wherein said insoluble semipermeable material of said first layer comprises ethyl cellulose, and wherein said second layer comprises hydroxypropylmethylcellulose acetate succinate (HPMC AS).

22. A method according to claim 21 , wherein said first layer further comprises a water soluble material comprising hydroxypropylmethylcellulose (HPMC).

23. A method for treating proctitis in a subject in need thereof, comprising rectally administering to the subject an effective amount of a pharmaceutical composition consisting of activated carbon.

Assignees

• Ferring Bv

Inventors

• Ekelund Mats

Classifications

• A61K2300/00

  Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00 · CPC title

• A61K9/0031

  Rectum, anus · CPC title

• A61K9/5047

  Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose · CPC title

• A61K9/2081

  with microcapsules or coated microparticles according to A61K9/50 · CPC title

• A61P1/00

  Drugs for disorders of the alimentary tract or the digestive system · CPC title